ADP-A2M4CD8
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for ADP-A2M4CD8, covering 2024-09-04 to 2026-04-07. Get the full timeline:
Most recent: Clinical Trial Update: ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) [Phase 1]